Head-to-head evidence
adalimumab-adbm (Cyltezo) vs SAR441566
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
SAR441566
Developed by Sanofi
NCT06073093 · Phase 2 · completed
The study randomized 264 participants to four SAR441566 dose regimens or placebo and used triple masking of participants, investigators, and outcome assessors. Its primary endpoint was the clinical ACR20 response at week 12, but results have not been posted, so whether the endpoint was met or missed cannot be assessed.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · SAR441566's landscape